Cargando…

Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease

Brain-derived neurotrophic factor (BDNF) is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington’s disease (HD), possibly because mutant huntingtin impairs its cortico-striatal transport, contributing to striatal neurodegeneration. The BDNF trophic pathway is a ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Zhen-Yi Andy, Byrne, Lauren M., Rodrigues, Filipe B., Tortelli, Rosanna, Johnson, Eileanoir B., Foiani, Martha S., Arridge, Marzena, De Vita, Enrico, Scahill, Rachael I., Heslegrave, Amanda, Zetterberg, Henrik, Wild, Edward J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876124/ https://www.ncbi.nlm.nih.gov/pubmed/33568689 http://dx.doi.org/10.1038/s41598-021-83000-x

Ejemplares similares

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease
por: Lowe, Alexander J, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021)

Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Characterizing White Matter in Huntington's Disease
por: Gregory, Sarah, et al.
Publicado: (2019)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study
por: Hassan, Yara Refaat, et al.
Publicado: (2022)

The use of wearable/portable digital sensors in Huntington's disease: A systematic review
por: Tortelli, Rosanna, et al.
Publicado: (2021)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Dynamics of Cortical Degeneration Over a Decade in Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2021)

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker
por: Mason, Sarah L., et al.
Publicado: (2018)

Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease
por: Wijeratne, Peter A., et al.
Publicado: (2021)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Timing of selective basal ganglia white matter loss in premanifest Huntington’s disease
por: Zeun, Paul, et al.
Publicado: (2022)

A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington’s Disease
por: Wijeratne, Peter A., et al.
Publicado: (2021)

Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington’s disease
por: Papoutsi, Marina, et al.
Publicado: (2022)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2017)

Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis
por: Banerjee, Gargi, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
por: Banerjee, Gargi, et al.
Publicado: (2020)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
por: Mansoor, Nina M., et al.
Publicado: (2021)

Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset
por: Nair, Akshay, et al.
Publicado: (2021)

An image‐based model of brain volume biomarker changes in Huntington's disease
por: Wijeratne, Peter A., et al.
Publicado: (2018)

Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
por: Zuccato, Chiara, et al.
Publicado: (2011)

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
por: Scahill, Rachael I, et al.
Publicado: (2020)

Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease
por: Wijeratne, Peter A., et al.
Publicado: (2020)

Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia
por: Zeitlberger, Anna M., et al.
Publicado: (2018)

A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study
por: Lipsmeier, Florian, et al.
Publicado: (2022)

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
por: Woollacott, Ione O. C., et al.
Publicado: (2018)

Testing a longitudinal compensation model in premanifest Huntington’s disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Neurofilament light-associated connectivity in young-adult Huntington’s disease is related to neuronal genes
por: McColgan, Peter, et al.
Publicado: (2022)

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease
por: Niemelä, Valter, et al.
Publicado: (2018)

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease
por: Sánchez-Valle, Raquel, et al.
Publicado: (2018)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s disease: evidence from the Young Adult Study
por: Langley, Christelle, et al.
Publicado: (2021)

Diffusion imaging in Huntington’s disease: comprehensive review
por: Estevez-Fraga, Carlos, et al.
Publicado: (2021)

Huntington’s Disease Clinical Trials Corner: February 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: August 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_na5tvu4lakql8o5a3j1lckrt4q